CCL28 promotes breast cancer growth and metastasis through MAPK-mediated cellular anti-apoptosis and pro-metastasis
| Autor: | Kai Yi Liu, Feng Juan Lin, Zhou Luo Ou, Hui Min Shi, Xiao Li Yang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
MAPK/ERK pathway Cancer Research MMP2 proliferation Apoptosis Breast Neoplasms Biology medicine.disease_cause Metastasis 03 medical and health sciences Mice 0302 clinical medicine Breast cancer breast cancer Cell Movement medicine Biomarkers Tumor Cell Adhesion metastasis Animals Humans Neoplasm Metastasis Cell Proliferation Mitogen-Activated Protein Kinase Kinases Cancer General Medicine Articles medicine.disease MAPK Xenograft Model Antitumor Assays Gene Expression Regulation Neoplastic 030104 developmental biology Oncology Matrix Metalloproteinase 9 Tumor progression CCL28 030220 oncology & carcinogenesis Chemokines CC Cancer research MCF-7 Cells Matrix Metalloproteinase 2 Female Carcinogenesis Signal Transduction |
| Zdroj: | Oncology Reports |
| ISSN: | 1791-2431 1021-335X |
| Popis: | Breast cancer is one of the most commonly diagnosed cancers worldwide and the second leading cause of cancer-related deaths among females. CCL28 (mucosa-associated epithelial chemokine, MEC), a CC subfamily chemokine, has been well studied in the process of inflammation, and recently increasing evidence indicates that CCL28 is related to tumor progression. However, little is known concerning its function in breast cancer. In the present study, we generated a CCL28-overexpressing breast cancer cell line MDA-MB-231HM/CCL28 from parental MDA-MB‑231HM cells. We found that overexpression of CCL28 promoted cell proliferation and tumor formation, and also enhanced migration, invasion and metastasis both in vitro and in vivo. Mechanistic studies revealed that CCL28 mediated intracellular activation of the mitogen-activated protein kinase (MAPK) signaling pathway to promote breast cancer cell proliferation and metastasis by upregulating anti-apoptotic protein Bcl-2 and suppressing cell adhesion protein β-catenin. However, overexpression of CCL28 did not influence the expression of metastasis‑related protein matrix metalloproteinase MMP2 and MMP9 and VEGF. Tissue sample analysis from animal models also indicated that overexpression of CCL28 was associated with enhanced pERK expression and reduced β-catenin expression in breast carcinomas. Thus, our results show for the first time that CCL28 contributes to breast cancer progression through the ERK/MAPK‑mediated anti-apoptotic and metastatic signaling pathway. Antagonists of CCL28 and the MAPK signaling pathway may be used synergistically to treat breast cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|